Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets

por Ashai, Nadia, Swain, Sandra M.
Publicado 2023

Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?

por Ewer, Michael S., Swain, Sandra M.
Publicado 2016

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

por Schlam, Ilana, Swain, Sandra M.
Publicado 2021

Targeting HER2-positive breast cancer: advances and future directions

por Swain, Sandra M., Shastry, Mythili, Hamilton, Erika
Publicado 2022

Potential and Pitfalls of Pharmacovigilance Databases in Oncology

por Schlam, Ilana, Ewer, Michael S., Swain, Sandra M.
Publicado 2023

Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age

por Swain, Sandra M., Nunes, Raquel, Yoshizawa, Carl, Rothney, Megan, Sing, Amy P.
Publicado 2015

Focus on You: Cancer clinical trials perspectives

por Robinson, Brandi N., Newman, Antoinette F., Wallington, Sherrie F., Swain, Sandra M.
Publicado 2016

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-cont...

por Miles, David, Baselga, José, Amadori, Dino, Sunpaweravong, Patrapim, Semiglazov, Vladimir, Knott, Adam, Clark, Emma, Ross, Graham, Swain, Sandra M.
Publicado 2013

Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Usi...

por Polito, Letizia, Shim, Jinjoo, Hurvitz, Sara A., Dang, Chau T., Knott, Adam, Du Toit, Yolande, Restuccia, Eleonora, Sanglier, Thibaut, Swain, Sandra M.
Publicado 2023

The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling

por Schlam, Ilana, Church, Sarah E., Hether, Tyler D., Chaldekas, Krysta, Hudson, Briana M., White, Andrew M., Maisonet, Emily, Harris, Brent T., Swain, Sandra M.
Publicado 2021

NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors

por Mansky, Patrick J., Wallerstedt, Dawn B., Sannes, Timothy S., Stagl, Jamie, Johnson, Laura Lee, Blackman, Marc R., Grem, Jean L., Swain, Sandra M., Monahan, Brian P.
Publicado 2013

Erratum to “NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors”

por Mansky, Patrick J., Wallerstedt, Dawn B., Sannes, Timothy S., Stagl, Jamie, Johnson, Laura Lee, Blackman, Marc R., Grem, Jean L., Swain, Sandra M., Monahan, Brian P.
Publicado 2014

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination

por Swain, Sandra M., Tang, Gong, Lucas, Peter C., Robidoux, André, Goerlitz, David, Harris, Brent T., Bandos, Hanna, Geyer, Charles E., Rastogi, Priya, Mamounas, Eleftherios P., Wolmark, Norman
Publicado 2019

UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation

por Nelson, Ryan S., Seligson, Nathan D., Bottiglieri, Sal, Carballido, Estrella, Cueto, Alex Del, Imanirad, Iman, Levine, Richard, Parker, Alexander S., Swain, Sandra M., Tillman, Emma M., Hicks, J. Kevin
Publicado 2021

Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings

por Smith, D. Max, Peshkin, Beth N., Springfield, T. Blaise, Brown, Ryan P., Hwang, Elizabeth, Kmiecik, Susanna, Shapiro, Richard, Eldadah, Zayd, Lundergan, Conor, McAlduff, Joel, Levin, Bonnie, Swain, Sandra M.
Publicado 2020

Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia

por Schairer, Catherine, Soliman, Amr S, Omar, Sherif, Khaled, Hussein, Eissa, Saad, Ayed, Farhat Ben, Khalafallah, Samir, Ayoub, Wided Ben, Kantor, Elizabeth D, Merajver, Sofia, Swain, Sandra M, Gail, Mitchell, Brown, Linda Morris
Publicado 2013

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer

por Khoury, Katia, Tan, Antoinette R., Elliott, Andrew, Xiu, Joanne, Gatalica, Zoran, Heeke, Arielle L., Isaacs, Claudine, Pohlmann, Paula R., Schwartzberg, Lee S., Simon, Michael, Korn, W. Michael, Swain, Sandra M., Lynce, Filipa
Publicado 2020

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

por Tripathy, Debu, Brufsky, Adam, Cobleigh, Melody, Jahanzeb, Mohammad, Kaufman, Peter A., Mason, Ginny, O'Shaughnessy, Joyce, Rugo, Hope S., Swain, Sandra M., Yardley, Denise A., Chu, Laura, Li, Haocheng, Antao, Vincent, Hurvitz, Sara A.
Publicado 2019

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

por Swain, Sandra M., Macharia, Harrison, Cortes, Javier, Dang, Chau, Gianni, Luca, Hurvitz, Sara A., Jackisch, Christian, Schneeweiss, Andreas, Slamon, Dennis, Valagussa, Pinuccia, du Toit, Yolande, Heinzmann, Dominik, Knott, Adam, Song, Chunyan, Cortazar, Patricia
Publicado 2022

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

por Kaufman, Peter A, Bloom, Kenneth J, Burris, Howard, Gralow, Julie R, Mayer, Musa, Pegram, Mark, Rugo, Hope S, Swain, Sandra M, Yardley, Denise A, Chau, Miu, Lalla, Deepa, Yoo, Bongin, Brammer, Melissa G, Vogel, Charles L
Publicado 2014